Surging Raw Material Prices and Procurement Costs
First written in FY2023-Q2. 2 of 2 entries say "Materialised", first in FY2023-Q2. Latest entry: FY2024.
Qol Holdings moved to the "Worse" side of this theme in 2022, 1 year after the typical company in this theme (2021).
0 other companies' latest entry also says "Materialised".
- FY2024MaterialisedAnnual report
「In the pharmaceutical manufacturing and marketing business, we are working to realize synergies from bringing Daiichi Sankyo Espha Co., Ltd. into the Group. We have also continued promoting sales of the novel coronavirus antigen test kit “Tegarna® Stick SARS-CoV-2 Ag,” launched in December 2022, in addition to our existing products. However, the decline in revenue resulting from the drug price revision, surging raw material prices, factory repairs and other factors affected business performance.」
It states that surging raw material prices and factory repairs, among other factors, actually affected the performance of the pharmaceutical manufacturing and marketing business. - FY2023-Q2MaterialisedAnnual report
「In the pharmaceutical manufacturing and marketing business, revenue and profit declined, mainly because the impact of surging raw material prices and procurement costs was particularly significant, in addition to the decline in revenue resulting from the drug price revision.」
It states that surging raw material prices and procurement costs had a significant impact on the pharmaceutical manufacturing and marketing business, resulting in lower revenue and profit.